Peginterferon to prevent relapse after stopping hepatitis B treatment
Part of Digestive system, Infections clinical trials.
This study tests whether a medicine called peginterferon can help lower the chance of hepatitis B coming back after you stop your current antiviral treatment. It may be an option for people with well-controlled hepatitis B and low levels of surface antigen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 65
- Have chronic hepatitis B that is e-antigen negative (HBeAg-negative)
- Taking a hepatitis B antiviral medicine for at least 3 years with no detectable virus
- HBsAg level 1000 or lower
- Liver stiffness score 7.4 kPa or lower (no significant liver damage)
- Willing to stop your current hepatitis B medicine and try a peginterferon injection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a retreatment with pegylated interferon for people with chronic hepatitis B who have previously received interferon therapy and have seen their hepatitis B surface antigen (HBsAg) levels drop by at least half. The goal is to see if this retreatment can completely clear the virus from the blood.
This study tests a lower dose of pegylated interferon for people with chronic hepatitis B whose virus levels dropped significantly during a previous interferon treatment. It aims to see if a second round can further reduce or clear the virus.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
This study looks at whether extra treatment with peginterferon (a drug that boosts the immune system) can help lower the amount of hidden hepatitis B virus in the liver after you've already reached clinical cure. You'll have two liver biopsies to measure this, and the findings may help prevent the virus from coming back.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.